Mizuho raised the firm’s price target on Hologic to $95 from $92 and keeps a Buy rating on the shares. The company reported a "sizable" fiscal Q2 beat on two extra selling days, a $20M beat in COVID testing, and "sizable outperformances" across Breast Health and GYN Surgical, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HOLX:
- Hologic raises FY23 EPS view to $3.75-$3.95 from $3.55-$3.85, consensus $3.75
- Hologic sees Q3 adjusted EPS 83c-93c, consensus 88c
- Hologic reports Q2 adjusted EPS $1.06, consensus 88c
- HOLX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Hologic price target raised to $92 from $90 at Mizuho
